Journals / Mersin Üniversitesi Sağlık Bilimleri Dergisi / 2021 / Cilt: 14 - Sayı: 1

The frequency and importance of combined non-alcoholic fatty liver disease in patients with chronic viral hepatitis

Kronik viral hepatitli olgularda kombine non-alkolik yağlı karaciğer hastalığının sıklığı ve önemi

Pages
77–86
Publication Date
2021-04-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It will be important in terms of the course of disease that steatohepatosis accompanying chronic viral hepatitis cases should be stated in pathology reports.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of the study is to determine the hepatosteatosis diagnosed as chronic viral hepatitis in liver biopsies and to reveal the relationship with the parameters in scoring systems and thus to predict the course of the disease.
📊
Key Findings & Data:Method: Preparations of 110 cases diagnosed with chronic viral hepatitis in two different university hospitals were re-evaluated and scored based on modified histologic activity index and nonalcoholic fatty liver disease activity score (NAS) scoring system.
💡
Conclusion & Impact:It will be important in terms of the course of disease that steatohepatosis accompanying chronic viral hepatitis cases should be stated in pathology reports.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:kronik hepatit · nonalkolik yağlı karaciğer hastalığı · fibrozis

Abstract

Aim: The aim of the study is to determine the hepatosteatosis diagnosed as chronic viral hepatitis in liver biopsies and to reveal the relationship with the parameters in scoring systems and thus to predict the course of the disease. Method: Preparations of 110 cases diagnosed with chronic viral hepatitis in two different university hospitals were re-evaluated and scored based on modified histologic activity index and nonalcoholic fatty liver disease activity score (NAS) scoring system. The relationship between the parameters of these two scoring systems was examined. Results: Hepatosteatosis accompanies our chronic hepatitis C cases with a rate of 34.8% and chronic hepatitis B cases with a rate of 44.8%. As the steatosis score increases, the fibrosis scores of the cases also increase. Conclusion: Chronic viral hepatitis and nonalcoholic fatty liver disease (NAFLD), which are common chronic liver diseases, should not always be considered as separate entities. It should also be kept in mind that those can be occurred together. It will be important in terms of the course of disease that steatohepatosis accompanying chronic viral hepatitis cases should be stated in pathology reports.

Özet

eden hepatosteatozun belirlenerek bunların skorlama sistemlerindeki parametreler ile ilişkisinin ortaya konması ve böylelikle hastalığın seyri ile ilgili öngörüde bulunmaktır. Yöntem: İki farklı üniversite hastanesinde kronik viral hepatit tanısı almış 110 olguya ait preperatlar yeniden değerlendirilmiş ve modifiye histolojik aktivite indeksi ve nonalkolik yağlı karaciğer hastalığı aktivite skoru (NAS) skorlama sistemleri esas alınarak skorlanmıştır. Bu iki skorlama sistemine ait parametreler arasındaki ilişki incelenmiştir. Bulgular: Hepatosteatoz, kronik hepatit C’li olgularımıza %34.8 oranında, kronik hepatit B olgularımıza ise %44.8 oranında eşlik etmektedir. Steatoz skoru arttıkça olgulara ait fibrozis skorları da artmaktadır. Sonuç: Sık görülen kronik karaciğer hastalıkları olan kronik viral hepatit ve nonalkolik yağlı karaciğer hastalığı (NAFLD) her zaman ayrı antiteler olarak kabul edilmemeli, birlikte görülebileceği de akılda tutulmalıdır. Kronik viral hepatitli olgulara eşlik eden steatohepatozun da patoloji raporlarında belirtilmesi hastalığın seyri açısından önem arz edecektir.

🔖

Cite This Article

TUNCEL, F., DUMAN, A. A. (2021). The frequency and importance of combined non-alcoholic fatty liver disease in patients with chronic viral hepatitis. Mersin Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 14 - Sayı: 1, 77–86. https://ajindex.com/articles/127503

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Kaynaklar 1. Liang J, Liu F, Wang F et al. A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. Hindawi BioMed Research International 2017
  2. http://dx.doi.org/10.1155/2017/8793278. 2. Williams R. Global challenges in liver disease. Hepatology, 2006
  3. 44 (3): 521–526. 3. Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis, Cellular and Molecular Life Sciences. 2016
  4. 73 (10): 1969–1987. 4. Minakari M, Molaei M, Shalmani HM, et al. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. European Journal of Gastroenterology and Hepatology. 2009
  5. 21(5): 512–516. 5. Bondini S, Kallman J, Wheeler A, et al. Impact of nonalcoholic fatty liver disease on chronic hepatitis B. Liver International. 2007
  6. 27 (5): 607–611. 6. Morales MA, Sendra C, Romero-Gomez M. Hepatitis B and NAFLD: Lives cossed. Annals of Hepatology.2017
  7. 16(2): 185-187. 7. Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis. World Journal of Gastroenterology.2015
  8. 21(16):12989-12995. 8. Yasui K, Harano Y, Mitsuyoshi H, et al. Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol 2010
  9. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995
  10. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring sysytem for nonalcholic fatty liver disease. Hepatology. 2005
  11. Yilmaz B, Koklu S, Buyukbayram H, et al. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis. Afri Health Sci. 2015
  12. 15(3):714-8. doi: http://dx.doi.org/10.4314/ahs.v15i3.3 12. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004
  13. 11(2):97- 107. 13. Schiff E, Sorell M, Maddrey W. Disease of the Liver. 6th ed. Philadelphia: Lippincott-Williams and Wilkins
  14. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006
  15. 13(2):73-80. 15. Yoon EJ, Hu KQ. Hepatitis C virus (HCV) infection and hepatic steatosis. Int J Med Sci 2006
  16. 3(2):53-56. 16. Hwang SJ, Luo JC, Chu C